2019 Vaccine Guide & Insert - VG13

02/22/19

Catch-up vaccination

Anatomic or functional asplenia (including sickle cell
disease), persistent complement component deficiency,
eculizumab use:
y Bexsero: 2-dose series at least 1 month apart
y Trumenba: 3-dose series at 0, 1-2, 6 months
Bexsero and Trumenba are not interchangeable; the same
product should be used for all doses in a series.
For additional meningococcal vaccination information, see
meningococcal MMWR publications at www.cdc.gov/vaccines/
hcp/acip-recs/vacc-specific/mening.html.

Special situations

y MenB vaccine may be administered based on individual
clinical decision to adolescents not at increased risk age
16-23 years (preferred age 16-18 years):
y Bexsero: 2-dose series at least 1 month apart
y Trumenba: 2-dose series at least 6 months apart; if dose 2 is
administered earlier than 6 months, administer a 3rd dose at
least 4 months after dose 2.

Clinical discretion

Meningococcal serogroup B vaccination
(minimum age: 10 years [MenB-4C, Bexsero;
MenB-FHbp, Trumenba])

Note: Menactra should be administered either before
or at the same time as DTaP. For MenACWY booster dose
recommendations for groups listed under "Special situations"
above and additional meningococcal vaccination information,
see meningococcal MMWR publications at www.cdc.gov/
vaccines/hcp/acip-recs/vacc-specific/mening.html.

First-year college students who live in residential housing
(if not previously vaccinated at age 16 years or older) or
military recruits:
y 1 dose Menveo or Menactra

Travel in countries with hyperendemic or epidemic
meningococcal disease, including countries in the African
meningitis belt or during the Hajj (wwwnc.cdc.gov/travel/):
y Children age less than 24 months:
- Menveo (age 2-23 months):
 Dose 1 at 8 weeks: 4-dose series at 2, 4, 6, 12 months
 Dose 1 at 7-23 months: 2-dose series (dose 2 at least
12 weeks after dose 1 and after the 1st birthday)
- Menactra (age 9-23 months):
 2-dose series (dose 2 at least 12 weeks after dose 1; dose
2 may be administered as early as 8 weeks after dose 1 in
travelers)
y Children age 2 years or older: 1 dose Menveo or Menactra

*

To Fax: 1.800.329.9109 24 Hrs

Centers for Disease Control and Prevention | Recommended Child and Adolescent Immunization Schedule, United States, 2019 | Page 7

Anatomic or functional asplenia (including sickle cell
disease), HIV infection, persistent complement component
deficiency, eculizumab use:
y Menveo
- Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months
- Dose 1 at age 7-23 months: 2-dose series (dose 2 at least
12 weeks after dose 1 and after the 1st birthday)
- Dose 1 at age 24 months or older: 2-dose series at least
8 weeks apart
y Menactra
- Persistent complement component deficiency:
 Age 9-23 months: 2 doses at least 12 weeks apart
 Age 24 months or older: 2 doses at least 8 weeks apart
- Anatomic or functional asplenia, sickle cell disease, or
HIV infection:
 Age 9-23 months: Not recommended
 24 months or older: 2 doses at least 8 weeks apart
 Menactra must be administered at least 4 weeks after
completion of PCV13 series.

Special situations

y Age 13-15 years: 1 dose now and booster at age
16-18 years (minimum interval: 8 weeks)
y Age 16-18 years: 1 dose

Catch-up vaccination

y 2-dose series: 11-12 years, 16 years

Routine vaccination

Meningococcal serogroup A,C,W,Y vaccination
(minimum age: 2 months [MenACWY-CRM,
Menveo], 9 months [MenACWY-D, Menactra])

International travel
y Infants age 6-11 months: 1 dose before departure;
revaccinate with 2 doses at 12-15 months (12 months for
children in high-risk areas) and dose 2 as early as 4 weeks later.
y Unvaccinated children age 12 months and older: 2-dose
series at least 4 weeks apart before departure

Special situations

y Unvaccinated children and adolescents: 2 doses at least
4 weeks apart
y The maximum age for use of MMRV is 12 years.

To Order: 1.800.P.SCHEIN (1.800.772.4346) 8am-8:30pm, et

y Egg allergy, hives only: Any influenza vaccine appropriate for
age and health status annually
y Egg allergy more severe than hives (e.g., angioedema,
respiratory distress): Any influenza vaccine appropriate for
age and health status annually in medical setting under
supervision of health care provider who can recognize and
manage severe allergic conditions
y LAIV should not be used for those with a history of
severe allergic reaction to any component of the vaccine
(excluding egg) or to a previous dose of any influenza
vaccine, children and adolescents receiving concomitant
aspirin or salicylate-containing medications, children age
2 through 4 years with a history of asthma or wheezing,
those who are immunocompromised due to any cause
(including immunosuppression caused by medications and
HIV infection), anatomic and functional asplenia, cochlear
implants, cerebrospinal fluid-oropharyngeal communication,
close contacts and caregivers of severely immunosuppressed
persons who require a protected environment, pregnancy,
and persons who have received influenza antiviral
medications within the previous 48 hours.

Special situations

y 1 dose any influenza vaccine appropriate for age and health
status annually (2 doses separated by at least 4 weeks for
children 6 months-8 years who did not receive at least
2 doses of influenza vaccine before July 1, 2018)

Routine vaccination

Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV],
18 years [RIV])

y 2-dose series at 12-15 months, 4-6 years
y Dose 2 may be administered as early as 4 weeks after dose 1.

Routine vaccination

Measles, mumps, and rubella vaccination
(minimum age: 12 months for routine vaccination)

Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019

y Only trivalent OPV (tOPV) counts toward the U.S. vaccination
requirements. For guidance to assess doses documented as
"OPV," see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w.
y For other catch-up guidance, see Table 2.

Notes
http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html http://wwwnc.cdc.gov/travel/ http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html http://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w http://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w
2019 Vaccine Guide & Insert

Table of Contents for the Digital Edition of 2019 Vaccine Guide & Insert
